|
1
|
Cormier JN and Pollock RE: Soft tissue
sarcomas. CA Cancer J Clin. 54:94–109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liao YX, Zhou CH, Zeng H, Zuo DQ, Wang ZY,
Yin F, Hua YQ and Cai ZD: The role of the CXCL12-CXCR4/CXCR7 axis
in the progression and metastasis of bone sarcomas (Review). Int J
Mol Med. 32:1239–1246. 2013.PubMed/NCBI
|
|
3
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang Y, Ludwig J and Janku F: Targeted
therapies for advanced Ewing sarcoma family of tumors. Cancer Treat
Rev. 41:391–400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McTiernan A, Jinks RC, Sydes MR, Uscinska
B, Hook JM, van Glabbeke M, Bramwell V, Lewis IJ, Taminiau AH,
Nooij MA, et al: Presence of chemotherapy-induced toxicity predicts
improved survival in patients with localised extremity osteosarcoma
treated with doxorubicin and cisplatin: A report from the European
Osteosarcoma Intergroup. Eur J Cancer. 48:703–712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferrari S, Ruggieri P, Cefalo G, Tamburini
A, Capanna R, Fagioli F, Comandone A, Bertulli R, Bisogno G,
Palmerini E, et al: Neoadjuvant chemotherapy with methotrexate,
cisplatin, and doxorubicin with or without ifosfamide in
nonmetastatic osteosarcoma of the extremity: An Italian sarcoma
group trial ISG/OS-1. J Clin Oncol. 30:2112–2118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khaw AK and Hande MP, Kalthur G and Hande
MP: Curcumin inhibits telomerase and induces telomere shortening
and apoptosis in brain tumour cells. J Cell Biochem. 114:1257–1270.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
James MI, Iwuji C, Irving G, Karmokar A,
Higgins JA, Griffin-Teal N, Thomas A, Greaves P, Cai H, Patel SR,
et al: Curcumin inhibits cancer stem cell phenotypes in ex vivo
models of colorectal liver metastases, and is clinically safe and
tolerable in combination with FOLFOX chemotherapy. Cancer Lett.
364:135–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blakemore LM, Boes C, Cordell R and Manson
MM: Curcumin-induced mitotic arrest is characterized by spindle
abnormalities, defects in chromosomal congression and DNA damage.
Carcinogenesis. 34:351–360. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Patil S, Lis LG, Schumacher RJ, Norris BJ,
Morgan ML, Cuellar RA, Blazar BR, Suryanarayanan R, Gurvich VJ and
Georg GI: Phosphonooxymethyl prodrug of triptolide: Synthesis,
physicochemical characterization, and efficacy in human colon
adenocarcinoma and ovarian cancer xenografts. J Med Chem.
58:9334–9344. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen X, Guo J, Bao J, Lu J and Wang Y: The
anticancer properties of Salvia miltiorrhiza Bunge (Danshen): A
systematic review. Med Res Rev. 34:768–794. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhuang SR, Chiu HF, Chen SL, Tsai JH, Lee
MY, Lee HS, Shen YC, Yan YY, Shane GT and Wang CK: Effects of a
Chinese medical herbs complex on cellular immunity and
toxicity-related conditions of breast cancer patients. Br J Nutr.
107:712–718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen J, Xie J, Jiang Z, Wang B, Wang Y and
Hu X: Shikonin and its analogs inhibit cancer cell glycolysis by
targeting tumor pyruvate kinase-M2. Oncogene. 30:4297–4306. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Andújar I, Recio MC, Giner RM and Ríos JL:
Traditional Chinese medicine remedy to jury: The pharmacological
basis for the use of shikonin as an anticancer therapy. Curr Med
Chem. 20:2892–2898. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Andújar I, Ríos JL, Giner RM and Recio MC:
Pharmacological properties of shikonin-a review of literature since
2002. Planta Med. 79:1685–1697. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Anninga JK, Gelderblom H, Fiocco M, Kroep
JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic
adjuvant treatment for osteosarcoma: Where do we stand? Eur J
Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li S, Sun W, Wang H, Zuo D, Hua Y and Cai
Z: Research progress on the multidrug resistance mechanisms of
osteosarcoma chemotherapy and reversal. Tumour Biol. 36:1329–1338.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de C, arné Trécesson S, Guillemin Y,
Bélanger A, Bernard AC, Preisser L, Ravon E, Gamelin E, Juin P,
Barré B and Coqueret O: Escape from p21-mediated oncogene-induced
senescence leads to cell dedifferentiation and dependence on
anti-apoptotic Bcl-xl and MCL1 proteins. J Biol Chem.
286:12825–12838. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
PosthumaDeBoer J, Witlox MA, Kaspers GJ
and van Royen BJ: Molecular alterations as target for therapy in
metastatic osteosarcoma: A review of literature. Clin Exp
Metastasis. 28:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Momparler RL, Karon M, Siegel SE and Avila
F: Effect of adriamycin on DNA, RNA, and protein synthesis in
cell-free systems and intact cells. Cancer Res. 36:2891–2895.
1976.PubMed/NCBI
|
|
21
|
Tewey KM, Rowe TC, Yang L, Halligan BD and
Liu LF: Adriamycin-induced DNA damage mediated by mammalian DNA
topoisomerase II. Science. 226:466–468. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bilim VN, Tomita Y, Kawasaki T, Takeda M
and Takahashi K: Adriamycin (ADM) induced apoptosis in transitional
cell cancer (TCC) cell lines accompanied by p21 WAF1/CIP1
induction. Apoptosis. 2:207–213. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bilim V, Kawasaki T, Takahashi K and
Tomita Y: Adriamycin induced G2/M cell cycle arrest in transitional
cell cancer cells with wt p53 and p21(WAF1/CIP1) genes. J Exp Clin
Cancer Res. 19:483–488. 2000.PubMed/NCBI
|
|
24
|
Voorhees PM, Orlowski RZ, Mulkey F, Watson
P, Geyer S, Sanford BL, Bennett E, Chanan-Khan AA, Bloomfield CD
and Larson RA: Long-term outcomes for newly-diagnosed multiple
myeloma patients treated with pegylated liposomal doxorubicin and
bortezomib: Final results of CALGB (Alliance) 10301, a multicentre
phase II study. Br J Haematol. 171:373–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Taylor RC, Cullen SP and Martin SJ:
Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol
Cell Biol. 9:231–241. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oliver FJ, de la Rubia G, Rolli V,
Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of poly
(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from
an uncleavable mutant. J Biol Chem. 273:33533–33539. 1998.
View Article : Google Scholar : PubMed/NCBI
|
